Compare MKSI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKSI | DVA |
|---|---|---|
| Founded | 1961 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 14.9B |
| IPO Year | 1997 | 2003 |
| Metric | MKSI | DVA |
|---|---|---|
| Price | $192.13 | $190.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $406.93 | $222.29 |
| AVG Volume (30 Days) | ★ 1.4M | 803.5K |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | ★ 55.52 | N/A |
| EPS | 6.86 | ★ 10.27 |
| Revenue | $3,931,000,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $29.30 | $3.77 |
| Revenue Next Year | $20.55 | $4.15 |
| P/E Ratio | $28.86 | ★ $18.76 |
| Revenue Growth | ★ 9.62 | 6.46 |
| 52 Week Low | $134.74 | $101.00 |
| 52 Week High | $447.62 | $247.49 |
| Indicator | MKSI | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 55.12 |
| Support Level | N/A | $189.09 |
| Resistance Level | $222.30 | $197.83 |
| Average True Range (ATR) | 10.83 | 7.86 |
| MACD | -1.09 | 0.96 |
| Stochastic Oscillator | 35.32 | 75.00 |
MKS Inc delivers foundational technology solutions for leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. The company provides instruments, components, subsystems, systems, process control solutions, and specialty chemicals technology that improve process performance and optimize productivity. Its solutions address challenges of miniaturization and complexity in device manufacturing, enabling increased power, speed, and feature enhancement. MKS Inc operates through three divisions: Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Materials Solutions Division (MSD). The company operates in the United States, which generates maximum revenue, as well as China and other countries.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.